

Supplementary data

Supplementary Tables

Table S1. All Rare *PRKN* variants found in cases and controls.

Table S2. CNV detection methods parameters and performance compared to MLPA.

Table S3. *PRKN* CNV carriers in cases and controls

Table S4. Rare *PRKN* heterozygous SNVs and CNVs analysis for risk of PD using SKAT-O in different variant groups

Table S5. Rare *PRKN* heterozygous SNVs and CNVs analysis for Age at Onset of PD in different variant groups

Table S6. Rare *PRKN* SNVs and CNVs association analysis in PD from previous studies.

Table S1. All Rare *PRKN* variants found in cases and controls.

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
McGill University											
6	161769074	rs903465113:A:C	0.0E+00	2.0E-04	Uncertain	c.*2057T>G	0	1	3.2E-05	0	6.7E-05
6	161769083	rs886180554:A:C	1.5E-03	8.2E-04	Uncertain	c.*2048T>G	3	4	6.5E-05	0	1.0E-04
6	161769108	rs752358219:A:G	0.0E+00	2.0E-04	Uncertain	c.*2023T>C	0	1	3.0E-04	0	5.0E-04
6	161769111	6:161769111:G:A	0.0E+00	2.0E-04	Uncertain	c.*2020C>T	0	1	0	0	0
6	161769313	rs114587790:C:T	0.0E+00	2.0E-04	Likely benign	c.*1818G>A	0	1	6.8E-03	0	1.0E-04
6	161769314	6:161769314:G:A	0.0E+00	2.0E-04	Uncertain	c.*1817C>T	0	1	0	0	0
6	161769342	6:161769342:T:C	0.0E+00	4.1E-04	Uncertain	c.*1789A>G	0	2	0	0	0
6	161769436	rs77283740:C:T	5.8E-03	4.5E-03	Benign	c.*1695G>A	11	22	1.4E-02	1.7E-02	2.2E-03
6	161769446	rs187134044:T:C	4.9E-04	6.1E-04	Uncertain	c.*1685A>G	1	3	7.0E-04	0	1.3E-03
6	161769530	rs779851186:C:T	1.5E-03	0.0E+00	Uncertain	c.*1601G>A	3	0	2.0E-04	0	2.0E-04
6	161769531	rs889401575:G:A	4.9E-04	0.0E+00	Uncertain	c.*1600C>T	1	0	6.5E-05	0	1.0E-04
6	161769549	rs748008270:C:T	0.0E+00	2.0E-04	Uncertain	c.*1582G>A	0	1	6.5E-05	0	6.7E-05
6	161769581	rs567890129:T:C	0.0E+00	4.1E-04	Uncertain	c.*1550A>G	0	2	2.0E-04	0	4.0E-04
6	161769631	6:161769631:G:A	0.0E+00	2.0E-04	Uncertain	c.*1500C>T	0	1	0	0	0
6	161769669	rs11961229:G:T	0.0E+00	2.0E-04	Benign	c.*1462C>A	0	1	7.4E-03	0	0
6	161769708	6:161769708:G:A	0.0E+00	6.1E-04	Uncertain	c.*1423C>T	0	3	0	0	0

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	161769724	rs11961237:G:A	0.0E+00	2.0E-04	Benign	c.*1407C>T	0	1	7.3E-03	0	0
6	161769745	rs140107485:T:C	8.8E-03	6.1E-03	Uncertain	c.*1386A>G	18	30	1.5E-03	0	2.5E-03
6	161769850	rs571904443:G:A	9.7E-04	0.0E+00	Uncertain	c.*1281C>T	2	0	6.5E-05	3.3E-03	0
6	161769879	rs77926621:G:A	5.9E-03	5.3E-03	Benign	c.*1252C>T	11	26	9.8E-03	1.7E-02	2.2E-03
6	161769943	6:161769943:T:C	4.9E-04	0.0E+00	Uncertain	c.*1188A>G	1	0	0	0	0
6	161770125	6:161770125:T:C	0.0E+00	2.0E-04	Uncertain	c.*1006A>G	0	1	0	0	0
6	161770240	rs572345942:TTATC:T	7.3E-03	6.5E-03	Uncertain	c.*887_*890delGATA	15	32	4.8E-03	0	6.7E-03
6	161770311	rs74701717:T:A	5.8E-03	5.5E-03	Benign	c.*820A>T	11	27	2.1E-02	1.7E-02	2.3E-03
6	161770408	rs895132585:T:C	0.0E+00	2.0E-04	Uncertain	c.*723A>G	0	1	0	0	0
6	161770478	rs760233938:C:T	1.0E-03	2.2E-04	Uncertain	c.*653G>A	2	1	0	0	0
6	161770547	rs567299724:C:A	0.0E+00	2.0E-04	Uncertain	c.*584G>T	0	1	3.2E-05	0	6.7E-05
6	161770584	6:161770584:A:G	0.0E+00	2.0E-04	Uncertain	c.*547T>C	0	1	0	0	0
6	161770929	6:161770929:CT:C	4.9E-04	0.0E+00	Uncertain	c.*201delA	1	0	6.5E-05	0	1.0E-04
6	161770961	rs998221207:C:T	4.9E-04	0.0E+00	Uncertain	c.*170G>A	1	0	0	0	0
6	161770968	rs1025324736:T:C	4.9E-04	0.0E+00	Uncertain	c.*163A>G	1	0	0	0	0
6	161771010	rs557142572:T:G	0.0E+00	2.0E-04	Uncertain	c.*121A>C	0	1	3.2E-05	0	0
6	161771035	rs916630868:C:T	4.9E-04	0.0E+00	Uncertain	c.*96G>A	1	0	3.3E-05	0	0
6	161771037	6:161771037:TG:del	0.0E+00	2.0E-04	Uncertain	c.*93_*94delA C	0	1	0	0	0

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	161771219	rs149953814:G:A	1.5E-03	2.7E-03	Uncertain	p.Pro437Leu	3	13	1.4E-03	0	2.3E-03
6	161771240	rs191486604:C:T	1.5E-03	0.0E+00	Likely Pathogenic	p.Gly430Asp	3	0	1.0E-04	0	2.0E-04
6	161771356	6:161771356:A:G	4.9E-04	0.0E+00	Uncertain	c.1286-113T>C	1	0	0	0	0
6	161771358	6:161771358:C:A	0.0E+00	2.0E-04	Uncertain	c.1286-115G>T	0	1	0	0	0
6	161781200	rs766915327:C:T	4.9E-04	0.0E+00	Likely Pathogenic	p.Arg402His	1	0	0	0	0
6	161781201	rs55830907:G:A	1.5E-03	1.6E-03	Benign	p.Arg402Cys	3	8	1.3E-03	0	1.3E-03
6	161781208	6:161781208:C:T	4.9E-04	0.0E+00	Uncertain	p.Glu399glu	1	0	0	0	0
6	161807881	rs375036403:G:A	0.0E+00	2.0E-04	Uncertain	p.Ala371Val	0	1	9.7E-05	0	1.0E-04
6	161969940	rs753655327:C:T	4.9E-04	0.0E+00	Likely benign	p.Pro343Pro	1	0	0	0	0
6	161969941	rs529808032:G:A	0.0E+00	2.0E-04	Uncertain	p.Pro343Leu	0	1	1.0E-04	0	3.0E-04
6	161969969	rs199657839:G:A	0.0E+00	2.0E-04	Benign	p.Arg334Cys	0	1	1.0E-04	0	6.7E-05
6	161970012	rs144340740:A:G	4.9E-04	4.1E-04	Benign	p.Gly319Gly	2	2	9.9E-03	0	6.7E-05
6	161990320	rs115979402:C:A	4.9E-04	0.0E+00	Benign	c.933+67G>T	2	0	1.1E-02	0	0
6	161990344	rs77112335:T:C	3.4E-03	1.4E-03	Benign	c.933+43A>G	7	7	1.1E-02	0	1.0E-04
6	161990390	rs72480423:C:G	0.0E+00	2.0E-04	Uncertain	p.Glu310Asp	0	1	2.0E-04	0	3.0E-04
6	161990401	rs138920699:G:A	0.0E+00	4.1E-04	Uncertain	p.Leu307Leu	0	2	1.6E-03	0	2.9E-03

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	162206851	rs769230602:C:T	0.0E+00	2.0E-04	Likely Pathogenic	p.Arg275Gln	0	1	0	0	0
6	162206852	rs34424986:G:A	2.4E-03	2.9E-03	Pathogenic	p.Arg275Trp	5	14	2.2E-03	0	3.3E-03
6	162206892	rs9456711:T:C	1.5E-03	1.4E-03	Benign	p.Leu261Leu	3	7	4.9E-02	0	4.0E-04
6	162206905	6:162206905:T:C	4.9E-04	0.0E+00	Likely Pathogenic	p.His257Arg	1	0	0	0	0
6	162206909	rs150562946:G:A	4.9E-04	6.2E-04	Uncertain	p.Arg256Cys	1	3	5.0E-04	0	8.0E-04
6	162206948	rs765248676:G:A	5.0E-04	0.0E+00	Uncertain	c.735-8C>T	1	0	0	0	0
6	162206954	rs200157467:G:C	5.0E-04	0.0E+00	Uncertain	c.735-14C>G	1	0	3.2E-05	3.3E-03	0
6	162394349	rs137853054:G:A	9.7E-04	6.1E-04	Likely Pathogenic	p.Thr240Met	2	3	1.0E-04	0	2.0E-04
6	162394449	rs768779161:C:G	9.7E-04	4.1E-04	Likely Pathogenic	p.Glu207Gln	2	2	3.2E-05	0	6.7E-05
6	162394487	rs576565848:C:T	0.0E+00	2.0E-04	Uncertain	c.619-38G>A	0	1	0	0	0
6	162394492	rs751186019:G:C	0.0E+00	2.0E-04	Uncertain	c.619-43C>G	0	1	0	0	0
6	162475128	6:162475128:T:TA	0.0E+00	2.0E-04	Pathogenic	p.Ser205Ter	0	1	0	0	0
6	162475167	rs9456735:T:G	0.0E+00	8.2E-04	Benign	p.Met192Leu	0	4	1.7E-02	0	3.0E-04
6	162622166	rs140590552:G:T	0.0E+00	1.0E-03	Likely benign	p.Thr177Thr	0	5	3.2E-05	0	6.7E-05
6	162622175	rs147121590:G:A	6.3E-03	2.9E-03	Uncertain	p.Leu174Leu	13	14	9.0E-04	0	1.2E-03
6	162622179	rs781608005:G:A	0.0E+00	2.0E-04	Uncertain	p.Thr173Met	0	1	1.0E-04	0	1.0E-04

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	162622180	rs749094429:T:C	0.0E+00	2.0E-04	Uncertain	p.Thr173Ala	0	1	1.0E-04	0	6.7E-05
6	162622216	6:162622216:T:C	4.9E-04	0.0E+00	Likely Pathogenic	p.Lys161HGlu	1	0	0	0	0
6	162622239	rs55654276:G:C	0.0E+00	2.0E-04	Benign	p.Pro153Arg	0	1	4.6E-03	0.0E+00	0.0E+00
6	162622262	rs371890659:G:C	4.9E-04	4.1E-04	Likely Pathogenic	p.Ser145Arg	1	2	0	0	0
6	162622309	rs770006273:T:C	0.0E+00	2.0E-04	Uncertain	c.413-25A>G	0	1	9.7E-05	0	1.0E-04
6	162683592	rs771529549:TCAGTGTGCAGATGACAGCCAGCCCCACAGAGTCTCCTGG:T	4.9E-04	0.0E+00	Uncertain	p.Pro113ThrfsTer51	1	0	3.0E-04	0	5.0E-04
6	162683680	rs373593750:G:A	0.0E+00	2.0E-04	Uncertain	p.Arg97Trp	0	1	3.2E-05	0	0
6	162683683	rs377591051:C:T	4.9E-04	0.0E+00	Uncertain	p.Glu96Lys	1	0	0	0	0
6	162683693	rs200256562:C:T	0.0E+00	4.1E-04	Likely benign	p.Ala92Ala	0	2	0	0	0
6	162683699	rs767425151:G:A	4.9E-04	0.0E+00	Uncertain	p.Asn90Asn	1	0	9.7E-05	0	0
6	162683724	rs55774500:G:T	0.0E+00	1.4E-03	Benign	p.Ala82Glu	0	7	2.6E-03	3.3E-03	3.0E-03
6	162683750	rs139083077:C:T	4.9E-04	0.0E+00	Uncertain	p.Pro73Pro	1	0	3.3E-05	0	6.7E-05
6	162683759	rs750338686:C:T	0.0E+00	2.1E-04	Uncertain	p.Val70Val	0	1	0	0	0
6	162683827	6:162683827:A:AAAAAAG	5.1E-04	0.0E+00	Uncertain	c.172-31_172-30insCTTTTTT	1	0	0	0	0
6	162864307	rs79752410:C:T	3.6E-03	5.0E-03	Benign	c.171+35G>A	7	23	5.1E-03	2.0E-02	3.7E-03

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	162864308	rs374566506:G:A	5.1E-04	2.1E-04	Uncertain	c.171+34C>T	1	1	3.0E-04	0	4.0E-04
6	162864325	rs370823431:C:T	0.0E+00	2.1E-04	Uncertain	c.171+17G>A	0	1	3.2E-05	0	0
6	162864339	6:162864339:C:A	5.1E-04	0.0E+00	Uncertain	c.171+3G>T	1	0	0	0	0
6	162864346	rs137853059:A:T	5.1E-04	0.0E+00	Likely Pathogenic	p.Val56Glu	1	0	6.5E-05	0	6.7E-05
6	162864388	rs368134308:C:G	4.9E-04	0.0E+00	Likely Pathogenic	p.Arg42Pro	1	0	0	0	0
6	162864402	rs77795533:C:T	0.0E+00	6.1E-04	Benign	p.Pro37Pro	0	3	3.0E-02	0	5.0E-04
6	162864403	rs148990138:G:A	0.0E+00	2.0E-04	Uncertain	p.Pro37Leu	0	1	1.0E-04	0	1.0E-04
6	162864410	rs55777503:CC:T:C	1.5E-03	0.0E+00	Pathogenic	p.Gln34ArgfsTer5	3	0	3.0E-04	0	2.0E-04
6	162864462	rs148302761:G:A	0.0E+00	4.1E-04	Uncertain	p.Val17Val	0	2	9.7E-05	0	1.0E-04
6	162864465	rs143477190:C:T	3.9E-03	1.6E-03	Likely benign	p.Glu16Glu	8	8	2.6E-03	0	6.7E-05
6	162864519	rs769722629:T:C	4.9E-04	8.2E-04	Uncertain	c.8-14A>G	1	4	6.5E-05	0	1.0E-04
6	162864528	rs201760977:A:G	4.9E-04	0.0E+00	Likely benign	c.8-23T>C	1	0	5.0E-04	0	0
6	162864536	rs997012777:A:G	0.0E+00	2.0E-04	Uncertain	c.8-31T>C	0	1	0	0	0
6	162864548	6:162864548:C:A	0.0E+00	2.0E-04	Uncertain	c.8-43G>T	0	1	0	0	0
6	162864569	rs548127850:T:A	4.9E-04	0.0E+00	Uncertain	c.8-64A>T	1	0	0	0	0
6	162864588	rs548991430:A:G	4.9E-04	1.0E-03	Uncertain	c.8-83T>C	1	5	2.0E-04	0	1.0E-04

Columbia University

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	161769108	rs752358219:A:G	5.3E-04	9.9E-04	Uncertain	c.*2023T>C	1	1	3.0E-04	0	5.0E-04
6	161769181	rs376011629:A:CTGTGTGCT:A	5.3E-04	0.0E+00	Benign	c.*1941_*1949delAGCACACA G	1	0	1.0E-02	0	6.7E-05
6	161769313	rs114587790:C:T	0.0E+00	2.0E-03	Likely benign	c.*1818G>A	0	2	6.8E-03	0	1.0E-04
6	161769446	rs187134044:T:C	5.3E-04	0.0E+00	Uncertain	c.*1685A>G	1	0	7.0E-04	0	1.3E-03
6	161769669	rs11961229:G:T	5.3E-04	9.9E-04	Benign	c.*1462C>A	1	1	7.4E-03	0	0
6	161769710	rs748283584:T:C	5.3E-04	0.0E+00	Uncertain	c.*1421A>G	1	0	0	0	0
6	161769724	rs11961237:G:A	5.3E-04	9.9E-04	Benign	c.*1407C>T	1	1	7.3E-03	0	0
6	161769745	rs140107485:T:C	2.1E-03	3.0E-03	Uncertain	c.*1386A>G	4	3	1.5E-03	0	2.5E-03
6	161769748	6:161769748:A:G	5.3E-04	0.0E+00	Uncertain	c.*1383T>C	1	0	0	0	0
6	161769810	6:161769810:C:T	0.0E+00	9.9E-04	Uncertain	c.*1321G>A	0	1	0	0	0
6	161769850	rs571904443:G:A	5.3E-03	9.9E-04	Uncertain	c.*1281C>T	10	1	6.5E-05	3.3E-03	0
6	161769888	rs961026516:G:T	5.4E-04	1.0E-03	Uncertain	c.*1243C>A	1	1	2.0E-04	6.6E-03	2.0E-04
6	161769973	6:161769973:A:G	5.4E-04	0.0E+00	Uncertain	c.*1158T>C	1	0	0	0	0
6	161770003	rs770498017:G:C	5.3E-04	0.0E+00	Uncertain	c.*1128C>G	1	0	0	0	0
6	161770153	rs1039492436:A:G	0.0E+00	1.0E-03	Uncertain	c.*978T>C	0	1	0	0	0
6	161770240	rs572345942:TTATC:T	7.9E-03	4.0E-03	Uncertain	c.*890_*887delGATA	15	4	4.8E-03	0	6.7E-03
6	161770307	6:161770307:A:G	0.0E+00	9.9E-04	Uncertain	c.*824T>C	0	1	0	0	0

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	161770726	rs756738207:A:G	0.0E+00	9.9E-04	Uncertain	c.*405T>C	0	1	1.0E-04	0	1.0E-04
6	161770751	6:161770751:C:G	5.3E-04	0.0E+00	Uncertain	c.*380G>C	1	0	0	0	0
6	161771010	rs557142572:T:G	1.6E-03	0.0E+00	Uncertain	c.*121A>C	3	0	3.2E-05	0	0
6	161771037	6:161771037:T:G:del	5.3E-04	0.0E+00	Uncertain	c.*94_*93delC A	1	0	0	0	0
6	161771039	rs545573732:T:C	5.3E-04	0.0E+00	Uncertain	c.*92A>G	1	0	6.0E-04	0	8.0E-04
6	161771071	rs553007666:G:T	0.0E+00	2.0E-03	Uncertain	c.*60C>A	0	2	1.0E-04	0	0
6	161771157	rs182893847:T:G	5.3E-04	0.0E+00	Uncertain	p.Met458Leu	1	0	2.0E-04	0	1.0E-04
6	161771219	rs149953814:G:A	4.8E-03	3.0E-03	Uncertain	p.Pro437Leu	10	3	1.4E-03	0	2.3E-03
6	161771247	rs202021008:T:C	0.0E+00	9.9E-04	Uncertain	c.1286-4A>G	0	1	0	0	0
6	161771266	6:161771266:G:A	0.0E+00	9.9E-04	Uncertain	c.1286-23C>T	0	1	3.2E-05	0	0
6	161771325	6:161771325:C:G	0.0E+00	9.9E-04	Uncertain	c.1286-82G>C	0	1	0	0	0
6	161781074	rs920265563:C:A	5.3E-04	0.0E+00	Uncertain	c.1285+46G>T	1	0	0	0	0
6	161781146	rs531247345:C:T	5.3E-04	0.0E+00	Uncertain	p.Arg420His	1	0	3.2E-05	0	6.7E-05
6	161781201	rs55830907:G:A	1.1E-03	9.9E-04	Benign	p.Arg402Cys	2	1	1.3E-03	0	1.3E-03
6	161781242	6:161781242:G:A	0.0E+00	9.9E-04	Uncertain	c.1168-5C>T	0	1	0	0	0
6	161807874	6:161807874:A:G	0.0E+00	9.9E-04	Uncertain	p.His373His	0	1	0	0	0
6	161807897	rs56092260:G:A	5.3E-04	0.0E+00	Uncertain	p.Arg366Trp	1	0	3.0E-04	0	0
6	161969868	rs777171316:G:A	5.3E-04	0.0E+00	Likely benign	c.1083+18C>T	1	0	2.0E-04	0	0

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	161969941	rs529808032:G:A	1.1E-03	0.0E+00	Uncertain	p.Pro343Leu	2	0	1.0E-04	0	3.0E-04
6	161969952	rs546676036:C:T	5.3E-04	0.0E+00	Benign	p.Ala339Ala	1	0	3.2E-05	0	0
6	161969969	rs199657839:G:A	5.3E-04	0.0E+00	Benign	p.Arg334Cys	1	0	1.0E-04	0	6.7E-05
6	161970012	rs144340740:A:G	5.3E-04	9.9E-04	Benign	p.Gly319Gly	1	1	9.9E-03	0	6.7E-05
6	161990320	rs115979402:C:A	0.0E+00	9.9E-04	Benign	c.933+67G>T	0	1	1.1E-02	0	0
6	161990326	rs188958137:C:T	5.3E-04	0.0E+00	Uncertain	c.933+61G>A	1	0	9.7E-05	0	1.0E-04
6	161990344	rs77112335:T:C	1.6E-03	9.9E-04	Benign	c.933+43A>G	3	1	1.1E-02	0	1.0E-04
6	161990401	rs138920699:G:A	5.3E-04	1.0E-03	Uncertain	p.Leu307Leu	1	1	1.6E-03	0	2.9E-03
6	161990493	rs371634667:G:A	0.0E+00	9.9E-04	Uncertain	c.872-45C>T	0	1	3.2E-05	0	6.7E-05
6	161990506	rs143283042:T:C	1.6E-03	1.0E-03	Benign	c.872-58A>G	3	1	6.7E-03	0	6.7E-05
6	161990508	rs150733619:C:G	1.6E-03	1.0E-03	Benign	c.872-60G>C	3	1	6.6E-03	0	0
6	162206852	rs34424986:G:A	1.6E-03	2.0E-03	Pathogenic	p.Arg275Trp	3	2	2.2E-03	0	3.3E-03
6	162206859	rs143902760:G:A	5.3E-04	0.0E+00	Benign	p.Leu272Leu	1	0	0	0	0
6	162206900	rs750325162:T:C	0.0E+00	1.0E-03	Likely Pathogenic	p.Ile259Val	0	1	0	0	0
6	162206948	rs765248676:G:A	5.9E-04	0.0E+00	Uncertain	c.735-8C>T	1	0	0	0	0
6	162206954	rs200157467:G:C	2.4E-03	0.0E+00	Uncertain	c.735-14C>G	4	0	3.2E-05	3.3E-03	0
6	162394349	rs137853054:G:A	0.0E+00	2.0E-03	Likely Pathogenic	p.Thr240Met	0	2	1.0E-04	0	2.0E-04

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	162394354	rs114974496:G:A	5.3E-04	9.9E-04	Likely benign	p.Cys238Cys	1	1	3.6E-03	0	6.7E-05
6	162394379	rs571490973:G:A	5.3E-04	0.0E+00	Uncertain	p.Ala230Val	1	0	0	0	0
6	162394381	rs758048810:G:A	5.3E-04	0.0E+00	Uncertain	p.Ile229Ile	1	0	0	0	0
6	162475106	rs780523707:T:G	5.3E-04	0.0E+00	Uncertain	c.618+17A>C	1	0	3.2E-05	0	0
6	162475167	rs9456735:T:G	4.2E-03	5.0E-03	Benign	p.Met192Leu	8	4	1.7E-02	0	3.0E-04
6	162475268	6:162475268:C:T	5.3E-04	0.0E+00	Uncertain	c.535-62G>A	1	0	0	0	0
6	162475280	6:162475280:T:A	5.3E-04	0.0E+00	Uncertain	c.535-74A>T	1	0	0	0	0
6	162622175	rs147121590:G:A	1.1E-03	1.0E-03	Uncertain	p.Leu174Leu	2	1	9.0E-04	0	1.2E-03
6	162622180	rs749094429:T:C	5.3E-04	0.0E+00	Uncertain	p.Thr173Ala	1	0	1.0E-04	0	6.7E-05
6	162622239	rs55654276:G:C	1.1E-03	0.0E+00	Benign	p.Pro153Arg	2	0	4.6E-03	0	0
6	162622250	6:162622250:A:G	5.3E-04	0.0E+00	Uncertain	p.Tyr149Tyr	1	0	0	0	0
6	162622262	rs371890659:G:C	5.3E-04	0.0E+00	Likely Pathogenic	p.Ser145Arg	1	0	0	0	0
6	162683724	rs55774500:G:T	2.1E-03	2.0E-03	Benign	p.Ala82Glu	4	2	2.6E-03	3.3E-03	3.0E-03
6	162864378	rs763638925:G:A	5.3E-04	0.0E+00	Uncertain	p.Phe45Phe	1	0	6.5E-05	0	0
6	162864389	rs577232474:G:A	5.3E-04	0.0E+00	Likely Pathogenic	p.Arg42Cys	1	0	0	0	0
6	162864402	rs77795533:C:T	3.7E-03	3.0E-03	Benign	p.Pro37Pro	7	3	3.0E-02	0	5.0E-04
6	162864403	rs148990138:G:A	5.3E-04	0.0E+00	Uncertain	p.Pro37Leu	1	0	1.0E-04	0	1.0E-04

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	162864410	rs55777503:CC T:C	5.3E-04	0.0E+00	Pathogenic	p.Gln34ArgfsTer5	1	0	3.0E-04	0	2.0E-04
6	162864415	rs147757966:C:T	5.3E-04	0.0E+00	Likely Pathogenic	p.Arg33Gln	1	0	6.5E-05	0	6.7E-05
6	162864465	rs143477190:C:T	5.3E-04	9.9E-04	Likely benign	p.Glu16Glu	1	1	2.6E-03	0	6.7E-05
6	162864522	rs552574625:G:T	5.3E-04	9.9E-04	Uncertain	c.8-17C>A	1	1	0	0	0
6	162864528	rs201760977:A:G	0.0E+00	9.9E-04	Likely benign	c.8-23T>C	0	1	5.0E-04	0	0
Sheba Medical Center											
6	161769745	rs140107485:T:C	3.1E-03	9.7E-04	Uncertain	c.*1386A>G	4	1	1.5E-03	0.0E+00	2.5E-03
6	161769850	rs571904443:G:A	1.2E-02	5.8E-03	Uncertain	c.*1281C>T	15	6	6.5E-05	3.3E-03	0
6	161769854	6:161769854:T:C	0.0E+00	9.7E-04	Uncertain	c.*1277A>G	0	1	0	0	0
6	161769888	rs961026516:G:T	3.1E-03	4.8E-03	Uncertain	c.*1243C>A	4	5	2.0E-04	6.6E-03	2.0E-04
6	161769931	6:161769931:C:A	0.0E+00	9.7E-04	Uncertain	c.*1200G>T	0	1	0	0	0
6	161769958	rs916775178:A:G	7.7E-04	0.0E+00	Uncertain	c.*1173T>C	1	0	0	0	0
6	161769973	6:161769973:A:G	0.0E+00	9.7E-04	Uncertain	c.*1158T>C	0	1	0	0	0
6	161770111	rs563261042:G:A	7.7E-04	0.0E+00	Uncertain	c.*1020C>T	1	0	6.5E-05	0	0
6	161770240	rs572345942:TT ATC:T	5.4E-03	2.9E-03	Uncertain	c.*890_*887del GATA	7	3	4.8E-03	0	6.7E-03
6	161771023	rs984344247:T:C	0.0E+00	0.0E+00	Uncertain	c.*108A>G	1	0	3.2E-05	0	0
6	161771347	6:161771347:A:G	0.0E+00	9.7E-04	Uncertain	c.1286-104T>C	0	1	0	0	0
6	161771349	6:161771349:A:C	0.0E+00	9.7E-04	Uncertain	c.1286-106T>G	0	1	0	0	0

Chr	Pos	SNP	Freq A	Freq C	Sig	Anno	Count of A	Count of C	ALL genome AF	ASJ genome AF	NFE genome AF
6	161771351	6:161771351:T:C	0.0E+00	9.7E-04	Uncertain	c.1286-108A>G	0	1	0	0	0
6	161771357	6:161771357:G:T	7.7E-04	0.0E+00	Uncertain	c.1286-114C>A	1	0	0	0	0
6	161781201	rs55830907:G:A	7.7E-04	0.0E+00	Benign	p.Arg402Cys	1	0	1.3E-03	0	1.3E-03
6	161970057	rs200796582:T:C	7.7E-04	0.0E+00	Benign	c.934-22A>G	1	0	5.0E-04	0	9.0E-04
6	161990341	6:161990341:C:T	0.0E+00	9.7E-04	Uncertain	c.933+46G>A	0	1	0	0	0
6	161990401	rs138920699:G:A	0.0E+00	9.7E-04	Uncertain	p.Leu307Leu	0	1	1.6E-03	0	2.9E-03
6	161990510	6:161990510:TA:T	7.7E-04	0.0E+00	Uncertain	c.872-63delT	1	0	0	0	0
6	162206852	rs34424986:G:A	0.0E+00	9.7E-04	Pathogenic	p.Arg275Trp	0	1	2.2E-03	0	3.3E-03
6	162206948	rs765248676:G:A	8.0E-04	0.0E+00	Uncertain	c.735-8C>T	1	0	0	0	0
6	162206954	rs200157467:G:C	2.4E-03	2.0E-03	Uncertain	c.735-14C>G	3	2	3.2E-05	3.3E-03	0
6	162394495	6:162394495:C:T	7.7E-04	0.0E+00	Uncertain	c.619-46G>A	1	0	0	0	0
6	162683722	rs141825163:T:C	1.5E-03	0.0E+00	Uncertain	p.Thr83Ala	2	0	1.0E-04	3.3E-03	2.0E-04
6	162683724	rs55774500:G:T	7.7E-04	1.9E-03	Benign	p.Ala82Glu	1	2	2.6E-03	3.3E-03	3.0E-03
6	162683839	6:162683839:AA TGTC:del	7.7E-04	1.9E-03	Uncertain	c.172-47_172-42delGACATT	1	2	0	0	0
6	162864402	rs77795533:C:T	0.0E+00	9.7E-04	Benign	p.Pro37Pro	0	1	3.0E-02	0	5.0E-04
6	162864540	rs761274077:G:A	7.7E-04	0.0E+00	Uncertain	c.8-35C>T	1	0	3.2E-05	0	0

Abbreviations: Chr—Chromosome; Pos—Position; SNP—Single Nucleotide Polymorphism; Freq A—Frequency in Affected; Freq C—Frequency in Controls; Sig—Clinical Significance according to Varsome; Anno—Annotation; Count of A—Count of Affected; Count of C—Count of Controls; ALL genome AF—GnomAD genome allele frequency in all population; ASJ genome AF— GnomAD genome allele frequency in Ashkenazi Jewish population; NFE genome AF—GnomAD genome allele frequency in non-Finnish European population.

Table S2. CNV detection methods parameters and performance compared to MLPA

Methods	Parameters	TP	FP	TN	FN	Avail	FDR (%)	Sens (%)	Spe (%)
ExomeDepth	transition.probability = 1×10^{-6} expected.CNV.length = 100,000	36	16	385	1	438 /510	31	97	96
panelCN.MOPS	Default	42	215	252	1	510 /510	84	98	54

Abbreviations: CNV—copy Number Variation; MLPA—Multiplex Ligation-dependent Probe Amplification; TP—True Positive; FP—False Positive; TN—True Negative; FN—False Negative; Availability—available samples that passed quality control; FDR—False-discovery rate; Sens—Sensitivity; Spe—Specificity.

Table S3. PRKN CNV carriers in cases and controls.

Sample	CNV	Zyg	Status	Sex	AAS	Cohort	AAO
S29263	Exon 3 deletion	Het	A	F	41	McGill	NA
S29254	Exon 3 deletion	Hom	A	M	57	McGill	NA
S29243	Exon 9 duplication	Het	A	M	38	McGill	28
S20936	Exon 2 deletion	Het	A	NA	56	McGill	29
S35319	Exon 3 deletion	Hom	A	M	35	McGill	29
S29943	Exon 4 deletion	Het	A	M	47	McGill	34
S06128	Exon 3, 4 deletion	Het	A	M	44	McGill	39
S06163	Exon 2 duplication	Het	A	F	51	McGill	41
S34223	Exon 3 deletion	Het	A	M	55	McGill	53
S29772	Exon 3, 4 deletion	Het	A	F	68	McGill	64
S35169	Exon 2, 3, 4 duplication	Het	A	M	NA	McGill	64
S27094	Exon 3, 4 deletion	Het	A	M	88	McGill	68
S06087	Exon 3, 4 deletion	Het	A	F	74	McGill	73
S35181	Exon 9 duplication	Het	A	F	NA	McGill	85
S21652	Exon 2 duplication	Het	C	M	73	McGill	NA
S32929	Exon 2 deletion	Het	C	M	48	McGill	NA
S33018	Exon 2 deletion	Het	C	F	72	McGill	NA
S02762	Exon 3 deletion	Het	C	F	46	McGill	NA
S05433	Exon 6 deletion	Het	C	F	23	McGill	NA
S05512	Exon 2 deletion	Het	C	M	34	McGill	NA
S32915	Exon 3 deletion	Het	C	F	54	McGill	NA
S21514	Exon 6, 7, 8, 9, 10 duplication	Het	C	F	81	McGill	NA
S28305	Exon 2 duplication	Het	C	F	NA	McGill	NA
S32268	Exon 3, 4 deletion	Het	C	F	59	McGill	NA
S36521	Exon 3 deletion	Het	C	M	NA	McGill	NA
S36595	Exon 3 deletion	Het	C	M	NA	McGill	NA
S23082	Exon 3, 4 deletion	Hom	A	F	54	Columbia	16
S22919	Exon 3, 4 deletion	Het	A	M	52	Columbia	19
S23324	Exon 3 deletion	Het	A	F	70	Columbia	28
S38184	Exon 2 deletion	Het	A	F	41	Columbia	31
S38056	Exon 2 duplication	Het	A	M	45	Columbia	33
S38120	Exon 2 duplication	Het	A	F	39	Columbia	33
S33552	Exon 2 deletion	Het	A	M	36	Columbia	34
S33346	Exon 3, 4 deletion	Hom	A	M	37	Columbia	37
S22965	Exon 3, 4 deletion	Het	A	F	64	Columbia	38
S22969	Exon 3, 4 deletion	Het	A	F	63	Columbia	38
S33435	Exon 4 deletion	Het	A	M	44	Columbia	38
S33572	Exon 3 duplication	Het	A	M	56	Columbia	41

Sample	CNV	Zyg	Status	Sex	AAS	Cohort	AAO
S22587	Exon 3 duplication	Het	A	M	47	Columbia	47
S33609	Exon 2, 3, 4 deletion	Het	A	F	63	Columbia	52
S23201	Exon 2 duplication	Het	A	M	62	Columbia	54
S22906	Exon 2 duplication	Het	A	M	63	Columbia	63
S22645	Exon 2 duplication	Het	C	F	45	Columbia	NA
S22703	Exon 2, 3 duplication	Het	C	F	66	Columbia	NA
S23029	Exon 7 duplication	Het	C	F	74	Columbia	NA
S31155	Exon 5 deletion	Het	C	M	60	Columbia	NA
S31170	Exon 5 deletion	Het	C	F	42	Columbia	NA
S34477	Exon 11,12 deletion	Het	C	M	62	Columbia	NA
S34490	Exon 2, 3, 4 duplication	Het	C	M	73	Columbia	NA
S34561	Exon 12 deletion	Het	C	F	71	Columbia	NA
S35106	Exon 2 duplication	Het	A	M	73	Sheba	69
S29449	Exon 3, 4 deletion	Het	A	M	75	Sheba	74
S28720	Exon 4 duplication	Het	C	F	38	Sheba	NA

Samples are sorted by cohort and age at onset.

Abbreviations: CNV—Copy Number Variation; Zyg—Zygosity; AAS—Age At Sample; AAO—Age At Onset; Het—Heterozygote; Hom—Homozygote; A—Affected; C—Control; M—Male; F—Female; NA—Not Available.

Table S4. Rare *PRKN* heterozygous SNVs and CNVs analysis for risk of PD using SKAT-O in different variant groups

	<i>P</i> -values							
	Rare CADD		Rare functional		Rare nonsynonymous		Rare loss-of-function	
	SKAT-O	SKAT Burden	SKAT-O	SKAT Burden	SKAT-O	SKAT Burden	SKAT-O	SKAT Burden
McGill University								
SNV	0.38	0.24	0.29	0.17	0.23	0.13	0.81	0.77
CNV	NA	NA	NA	NA	NA	NA	0.90	0.85
SNV & CNV	0.38	0.24	0.29	0.17	0.23	0.13	0.81	0.57
Patho SNV	0.62	0.83	0.64	0.67	0.62	0.83	0.81	0.77
Patho SNV & CNV	0.69	0.50	0.99	0.81	0.85	0.68	0.81	0.77
No Benign SNV	0.62	0.83	0.64	0.67	0.62	0.83	0.81	0.57
No Benign SNV & CNV	0.69	0.50	0.99	0.81	0.85	0.68	0.81	0.57
Columbia University								
SNV	0.48	0.67	0.54	0.77	0.54	0.77	NA	NA
CNV	NA	NA	NA	NA	NA	NA	0.07	0.04
SNV & CNV	0.48	0.67	0.54	0.77	0.54	0.77	0.07	0.04
Patho SNV	0.12	0.07	0.12	0.07	0.12	0.07	NA	NA
Patho SNV & CNV	0.25	0.98	0.25	0.98	0.25	0.98	NA	NA
No Benign SNV	0.12	0.07	0.12	0.07	0.12	0.07	0.07	0.04
No Benign SNV & CNV	0.25	0.98	0.25	0.98	0.25	0.98	0.07	0.04
Sheba Medical Center								
SNV	0.70	0.68	0.52	0.41	0.52	0.41	NA	NA
CNV	NA	NA	NA	NA	NA	NA	0.61	0.61
SNV & CNV	0.70	0.68	0.52	0.41	0.52	0.41	0.61	0.61

Patho SNV	0.61	0.61	0.61	0.61	0.61	0.61	0.61	NA	NA
Patho SNV & CNV	0.61	0.61	0.62	0.61	0.62	0.61	0.61	NA	NA
No Benign SNV	0.61	0.61	0.61	0.61	0.61	0.61	0.61	0.61	0.61
No Benign SNV & CNV	0.61	0.61	0.62	0.61	0.62	0.61	0.61	0.61	0.61
Meta-Analysis									
SNV	0.75	0.54	0.69	0.48	0.63	0.42	0.53	0.53	0.50
CNV	NA	NA	NA	NA	NA	NA	NA	0.18	0.11
SNV & CNV	0.75	0.54	0.69	0.48	0.63	0.42	0.28	0.28	0.17
Patho SNV	0.56	0.39	0.57	0.50	0.56	0.39	0.53	0.53	0.50
Patho SNV & CNV	0.80	0.61	0.85	0.85	0.84	0.76	0.53	0.53	0.50
No Benign SNV	0.56	0.39	0.57	0.50	0.56	0.39	0.30	0.30	0.17
No Benign SNV & CNV	0.80	0.61	0.85	0.85	0.84	0.76	0.30	0.30	0.17

Abbreviations: SNV—Single Nucleotide Variant; CNV—Copy Number Variation; PD—Parkinson's Disease; Patho—pathogenic and likely pathogenic variants; No Benign—analysis excluding benign and likely benign variants; NA—not applicable, not enough variants for analysis.

a After Bonferroni correction, alpha = .0009 (56 tests)

Table S5. Rare *PRKN* heterozygous SNVs and CNVs analysis for Age at Onset of PD in different variant groups

	Rare CADD				Rare functional				Rare nonsynonymous				Rare loss-of-function			
	AAO with	AAO without	Coeff (95% CI)	<i>P</i> ^a	AAO with	AAO without	Coeff (95% CI)	<i>P</i> ^a	AAO with	AAO without	Coeff (95% CI)	<i>P</i> ^a	AAO with	AAO without	Coeff (95% CI)	<i>P</i> ^a
McGill University																
SNV	58.50	59.12	-0.61 (-6.69, 5.47)	0.84	59.43	59.10	0.38 (-5.26, 6.02)	0.90	58.31	59.12	-0.79 (-6.63, 5.06)	0.79	74.00	59.08	15.24 (-5.62, 36.10)	0.15
CNV	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	57.00	59.11	-2.73 (-17.55, 12.09)	0.72
SNV & CNV	58.50	59.12	-0.61 (-6.69, 5.47)	0.84	59.43	59.10	0.38 (-5.26, 6.02)	0.90	58.31	59.12	-0.79 (-6.63, 5.06)	0.79	62.67	59.09	3.28 (-8.80, 15.37)	0.59
Patho SNV	53.86	59.16	-5.26 (-13.18, 2.66)	0.19	56.38	59.14	-2.68 (-10.11, 4.74)	0.48	53.86	59.16	-5.26 (-13.18, 2.66)	0.19	74.00	59.08	15.24 (-5.62, 36.10)	0.15
Patho SNV & CNV	56.64	59.15	-2.53 (-8.88, 3.81)	0.43	57.92	59.13	-1.18 (-7.02, 4.67)	0.69	56.58	59.15	-2.56 (-8.64, 3.51)	0.41	74.00	59.08	15.24 (-5.62, 36.10)	0.15
No Benign SNV	53.86	59.16	-5.26 (-13.18, 2.66)	0.19	56.38	59.14	-2.68 (-10.11, 4.74)	0.48	53.86	59.16	-5.26 (-13.18, 2.66)	0.19	62.67	59.09	3.28 (-8.80, 15.37)	0.59
No Benign SNV & CNV	56.64	59.15	-2.53 (-8.88, 3.81)	0.43	57.92	59.13	-1.18 (-7.02, 4.67)	0.69	56.58	59.15	-2.56 (-8.64, 3.51)	0.41	62.67	59.09	3.28 (-8.80, 15.37)	0.59
Columbia University																
SNV	57.92	59.39	-1.47 (-6.24, 3.29)	0.54	57.50	59.40	-1.91 (-6.50, 2.67)	0.41	57.50	59.40	-1.91 (-6.50, 2.67)	0.41	NA	NA	NA	NA

CNV	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46.50	59.44	-12.94 (-22.31, -3.56)	0.007
SNV & CNV	57.92	59.39	-1.47 (-6.24, 3.29)	0.54	57.50	59.40	-1.91 (-6.50, 2.67)	0.41	57.50	59.40	-1.91 (-6.50, 2.67)	0.41	46.50	59.44	-12.94 (-22.31, -3.56)	0.007
Patho SNV	60.40	59.33	1.04 (-9.29, 11.36)	0.84	60.40	59.33	1.04 (-9.29, 11.36)	0.84	60.40	59.33	1.04 (-9.29, 11.36)	0.84	NA	NA	NA	NA
Patho SNV & CNV	59.35	59.34	0.004 (-5.64, 5.64)	0.99	59.35	59.34	0.004 (-5.64, 5.64)	0.99	59.35	59.34	0.004 (-5.64, 5.64)	0.99	NA	NA	NA	NA
No Benign SNV	60.40	59.33	1.04 (-9.29, 11.36)	0.84	60.40	59.33	1.04 (-9.29, 11.36)	0.84	60.40	59.33	1.04 (-9.29, 11.36)	0.84	46.50	59.44	-12.94 (-22.31, -3.56)	0.007
No Benign SNV & CNV	59.35	59.34	0.004 (-5.64, 5.64)	0.99	59.35	59.34	0.004 (-5.64, 5.64)	0.99	59.35	59.34	0.004 (-5.64, 5.64)	0.99	46.50	59.44	-12.94 (-22.31, -3.56)	0.007
Sheba Medical Center																
SNV	49.00	61.56	-11.89 (-36.12, 12.35)	.34	60.00	61.54	-1.83 (-19.00, 15.33)	.83	60.00	61.54	-1.83 (-19.00, 15.33)	.83	NA	NA	NA	NA
CNV	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	69.00	61.52	8.18 (-16.07, 32.43)	.51
SNV & CNV	49.00	61.56	-11.89 (-36.12, 12.35)	.34	60.00	61.54	-1.83 (-19.00, 15.33)	.83	60.00	61.54	-1.83 (-19.00, 15.33)	.83	69.00	61.52	8.18 (-16.07, 32.43)	.51
Patho SNV	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Patho SNV & CNV	NA	NA	NA	NA	71.0 0	61.51	8.25 (-16.0 3, 32.53)	.50	71.0 0	61.51	8.25 (-16.03, 32.53)	.50	NA	NA	NA	NA
No Benig n SNV	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	69.0 0	61.52	8.18 (-16.07, 32.43)	.51
No Benig n SNV & CNV	NA	NA	NA	NA	71.0 0	61.51	8.25 (-16.0 3, 32.53)	.50	71.0 0	61.51	8.25 (-16.03, 32.53)	.50	69.0 0	61.52	8.18 (-16.07, 32.43)	.51
Meta-Analysis																
SNV	57.8 6	59.82	-1.40 (- 5.10, 2.30)	.46	58.2 6	59.82	-1.04 (-4.51, 2.42)	.56	57.8 8	59.83	- 1.50(-5.0 2, 2.03)	.40	74.0 0	59.77	15.24 (-5.59, 36.06)	.15
CNV	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	51.3 3	59.82	-8.26 (-15.78, -0. 75)	.03
SNV & CNV	57.8 6	59.82	-1.40 (-5.10, 2.30)	.46	58.2 6	59.82	-1.04 (-4.51, 2.44)	.56	57.8 8	59.83	-1.50 (-5.02, 2.03)	.40	53.6 0	59.82	-5.56 (-12.63, 1.51)	.12
Patho SNV	56.5 8	59.80	-2.93(-9.2 0, 3.35)	.36	57.9 2	59.80	-1.42 (-7.43, 4.60)	.64	56.5 8	59.80	-2.93 (-9.20, 3.35)	.36	74.0 0	59.77	15.24 (-5.59, 36.06)	.15
Patho SNV & CNV	56.5 8	59.80	-2.93(-9.2 0, 3.35)	.36	57.9 2	59.80	-1.42 (-7.43, 4.60)	.64	56.5 8	59.80	-2.93 (-9.20, 3.35)	.36	53.6 0	59.82	-5.56 (-12.63, 1.51)	.12
No Benig n SNV	58.2 8	59.81	-1.12 (-5.32, 3.09)	.60	59.1 3	59.79	-0.33 (-4.32, 3.67)	.87	58.6 3	59.80	-0.92 (-4.99, 3.15)	.66	74.0 0	59.77	15.24 (-5.59, 36.06)	.15
No Benig n SNV	58.2 9	59.81	-1.12 (-5.32, 3.09)	.60	59.1 3	59.79	-0.33 (-4.32, 3.67)	.87	58.6 3	59.80	-0.92 (-4.99, 3.15)	.66	53.6 0	59.82	-5.56 (-12.63, 1.51)	.12

& CNV																	
----------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Abbreviations: SNV—Single Nucleotide Variant; CNV—Copy Number Variation; PD—Parkinson's Disease; Patho—pathogenic and likely pathogenic variants; No Benign—analysis excluding benign and likely benign variants.

^a After Bonferroni correction, alpha=.0018 (28 tests)

Table S6. Rare *PRKN* SNVs and CNVs association analysis in PD from previous studies^a.

Study	Number of carriers in patients (%)	Number of carriers in controls (%)	Analysis performed	Association with PD
Heterozygous PARK2 SNVs				
Bandrés-Ciga <i>et al.</i> , 2016	1/206 (0.5)	0/172 (0)	Full sequencing in cohort for SNV	Not significant
Benitez <i>et al.</i> , 2016	13/478 (2.7)	9/337 (2.7)	Full sequencing in cohort for SNV	Not significant
Bras <i>et al.</i> , 2008	1/61 (2)	0/126 (0)	Full sequencing in family for SNV	Not significant
Brooks <i>et al.</i> , 2009	14/249 (5.6)	7/276 (2.5)	Full sequencing in cohort for SNV	Not significant
Camargos <i>et al.</i> , 2009	2/42 (5)	0/126 (0)	Full sequencing in early onset patients for SNV, screening for specific SNVs in controls	Not significant
Clark <i>et al.</i> , 2006	5/99 (5)	0/105 (0)	Full sequencing in cohort for SNV	0.03
Fiala <i>et al.</i> , 2014	2/67 (3)	0/75 (0)	Full sequencing in early onset patients and controls for SNV	Not significant
Kay <i>et al.</i> , 2007	19/301 (6.3)	19/300 (6.3)	Full sequencing in cohort for SNV	Not significant
Klein <i>et al.</i> , 2005	1/64 (2)	0/100 (0)	Full sequencing in patients for SNV, screening for specific SNVs in controls	Not significant
Lesage <i>et al.</i> , 2008	10/159 (6.3)	0/170 (0)	Full sequencing in cohort for SNV	0.0006
Lincoln <i>et al.</i> , 2003	7/312 (2.2)	5/192 (2.6)	Full sequencing in cohort for SNV	Not significant
Macedo <i>et al.</i> , 2009	3/181 (1.7)	0/375 (0)	Full sequencing in patients for SNV, screening for specific SNVs in controls	0.03

Moura <i>et al.</i> , 2013	2/132 (1.5)	0/200 (0)	Full sequencing in patients for SNV, screening for specific SNVs in controls	Not significant
Sironi <i>et al.</i> , 2008	9/133 (6.8)	2/50 (4)	Full sequencing in patients for SNV, screening for specific SNVs in controls	Not significant
Spataro <i>et al.</i> , 2017	7/243 (2.9)	1/145 (0.7)	Full sequencing in cohort for SNV	Not significant
Wang <i>et al.</i> , 2008	12/240 (5.0)	0/104 (0)	Full sequencing in patients for SNV, screening for specific SNVs in controls	0.02
Heterozygous PARK2 CNVs				
Bandrés-Ciga <i>et al.</i> , 2016	1/206 (0.5)	0/172 (0)	Full sequencing in cohort for CNV	Not significant
Bras <i>et al.</i> , 2008	3/61 (5)	0/126 (0)	Full sequencing in family for CNV	0.03
Clark <i>et al.</i> , 2006	3/99 (3)	0/105 (0)	Full sequencing in cohort for CNV	Not significant
Fiala <i>et al.</i> , 2014	3/67 (4)	0/75 (0)	Full sequencing in early onset patients and controls for CNV	Not significant
Camacho <i>et al.</i> , 2012	11/40 (28)	1/120 (0.8)	Full sequencing in early onset patients and controls for CNV	<0.00001
Huttenlocher <i>et al.</i> , 2015	22/1393 (1.6)	373/40101 (0.9)	Full sequencing in cohort for CNV	0.02
Kay <i>et al.</i> , 2010	18/2073 (0.9)	16/1670 (1.0)	Full sequencing in cohort for CNV	Not significant
Lesage <i>et al.</i> , 2008	5/159 (3.1)	0/170 (0)	Full sequencing in cohort for CNV	0.03
Lincoln <i>et al.</i> , 2003	2/312 (0.6)	1/192 (0.5)	Full sequencing in cohort for CNV	Not significant
Macedo <i>et al.</i> , 2009	3/181 (1.7)	0/375 (0)	Full sequencing in patients for CNV, screening for specific CNVs in controls	0.03
Pankratz <i>et al.</i> , 2011	10/396 (2.5)	8/856 (0.9)	Full sequencing in cohort for CNV	0.04

Simon-Sanchez <i>et al.</i> 2008	3/272 (1.1)	4/274 (1.5)	Full sequencing in cohort for CNV	Not significant
Wang <i>et al.</i> 2008	4/240 (1.7)	0/104 (0)	Full sequencing in patients for CNV, screening for specific CNVs in controls	Not significant

^a This table shows previous heterozygous *PRKN* variants analysis on risk for PD. We wish to highlight the different type of analysis and variant inclusion criteria across studies. The association of heterozygous *PRKN* mutations in each study was calculated using Fisher's exact test.

Abbreviations: SNV—Single Nucleotide Variant; CNV—Copy Number Variation; PD—Parkinson's Disease.

Reference

- Bandrés-Ciga S, Price TR, Barrero FJ, Escamilla-Sevilla F, Pelegrina J, Arepalli S, *et al.* Genome-wide assessment of Parkinson's disease in a Southern Spanish population. *Neurobiol Aging* 2016; 45: 213. e3-. e9.
- Benitez BA, Davis AA, Jin SC, Ibanez L, Ortega-Cubero S, Pastor P, *et al.* Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. *Mol Neurodegener* 2016; 11(1): 29.
- Bras J, Guerreiro R, Ribeiro M, Morgadinho A, Januario C, Dias M, *et al.* Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. *BMC Neurol* 2008; 8(1): 1.
- Brooks J, Ding J, Simon-Sanchez J, Paisan-Ruiz C, Singleton A, Scholz S. Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control. *J Med Genet* 2009; 46(6): 375-81.
- Camacho JLG, Jaramillo NM, Gómez PY, Violante MR, Woehrlen CB, Vilatela MEA, *et al.* High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease. *Movement disorders* 2012; 27(8): 1047-51.
- Camargos ST, Dornas LO, Momeni P, Lees A, Hardy J, Singleton A, *et al.* Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: Phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. *Movement Disorders* 2009; 24(5): 662-6.
- Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, *et al.* Case-control study of the parkin gene in early-onset Parkinson disease. *Arch Neurol* 2006; 63(4): 548-52.
- Fiala O, Zahorakova D, Pospisilova L, Kucerova J, Matejckova M, Martasek P, *et al.* Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease. *PLoS One* 2014; 9(9).
- Huttenlocher J, Stefansson H, Steinberg S, Helgadottir HT, Sveinbjörnsdóttir S, Riess O, *et al.* Heterozygote carriers for CNVs in PARK2 are at increased risk of Parkinson's disease. *Hum Mol Genet* 2015; 24(19): 5637-43.
- Kay D, Stevens C, Hamza T, Montimurro J, Zabetian C, Factor S, *et al.* A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. *Neurology* 2010; 75(13): 1189-94.
- Kay DM, Moran D, Moses L, Poorkaj P, Zabetian CP, Nutt J, *et al.* Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. *Ann Neurol* 2007; 61(1): 47-54.
- Klein C, Djarmati A, Hedrich K, Schäfer N, Scaglione C, Marchese R, *et al.* PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. *European journal of human genetics* 2005; 13(9): 1086-93.
- Lesage S, Lohmann E, Tison F, Durif F, Dürr A, Brice A, *et al.* Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. *J Med Genet* 2008; 45(1): 43-6.
- Lincoln SJ, Maraganore DM, Lesnick TG, Bounds R, De Andrade M, Bower JH, *et al.* Parkin variants in North American Parkinson's disease: cases and controls. *Movement disorders: official journal of the Movement Disorder Society* 2003; 18(11): 1306-11.
- Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B, *et al.* Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society* 2009; 24(2): 196-203.

Moura KCV, Campos Junior M, de Rosso ALZ, Nicaretta DH, Pereira JS, Silva DJ, *et al.* Genetic analysis of PARK2 and PINK1 genes in Brazilian patients with early-onset Parkinson's disease. *Dis Markers* 2013; 35(3): 181-5.

Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, *et al.* Copy number variation in familial Parkinson disease. *PLoS One* 2011; 6(8).

Simon-Sanchez J, Scholz S, del Mar Matarin M, Fung HC, Hernandez D, Gibbs JR, *et al.* Genomewide SNP assay reveals mutations underlying Parkinson disease. *Hum Mutat* 2008; 29(2): 315-22.

Sironi F, Primignani P, Zini M, Tunesi S, Ruffmann C, Ricca S, *et al.* Parkin analysis in early onset Parkinson's disease. *Parkinsonism Relat Disord* 2008; 14(4): 326-33.

Spataro N, Roca-Umbert A, Cervera-Carles L, Vallès M, Anglada R, Pagonabarraga J, *et al.* Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients. *Movement Disorders* 2017; 32(1): 165-9.

Wang Y, Clark LN, Louis ED, Mejia-Santana H, Harris J, Cote LJ, *et al.* Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method. *Arch Neurol* 2008; 65(4): 467-74.